Haier Biomedical Achieves Dual No. 1 Ranking in Euromonitor’s Global Life Science Equipment Report
In a significant achievement, Haier Biomedical (SHA: 688139) has been recognized as the leading Chinese brand in the global market for laboratory equipment in life sciences, according to data released by Euromonitor International for 2025. This prestigious recognition underscores the company's prominent position in both overall global sales and foreign sales, making it a frontrunner in a competitive landscape dominated by established international manufacturers. This double ranking not only enhances Haier Biomedical's reputation but also supports its ongoing commitment to innovation and quality in the sector of laboratory equipment.
Euromonitor International stands as one of the leading independent market research firms worldwide. Its rankings serve as essential benchmarks in global procurement and industry analysis, confirming Haier Biomedical's competitive stance against other major players in the market. The dual acknowledgment is particularly significant for international partners, as it reinforces a sense of trust and credibility essential for procurement decisions in an industry where equipment reliability, regulatory compliance, and long-term service support are critical.
Haier Biomedical's international growth trajectory began with targeted initiatives and direct collaborations with organizations like UNICEF and WHO, addressing unmet needs and securing a leading position in solar-powered vaccine storage solutions. From this foundation, the company has expanded its distribution network to 160 countries through over 800 active sales partnerships. The current phase of the company's strategy focuses on implementing comprehensive operational capabilities across key regions, including local storage, sales, marketing, product planning, and R&D.
The company presently operates R&D centers in the UK, Italy, and Japan. Each center is dedicated to specific product lines, such as centrifuges, cold chain solutions, automated storage systems, incubators, and biological safety cabinets. In the UK and continental Europe, automation specialists and centrifuge technology experts provide localized support, ensuring compliance with Good Manufacturing Practices (GMP), air safety protocols, and sample processing cleanliness.
Haier Biomedical continues to enhance its service standards, developed initially in the USA and UK, replicating best practices across the EU, Southeast Asia, and South Asia. Notably, in the first quarter of 2026, revenue growth surged more than 50% in Germany, Australia, and Canada, while Eastern Europe, South Asia, and Brazil reported over a 100% year-over-year growth. Notably, sales of centrifuges and incubators doubled during this period, underscoring the company's rapid market penetration.
Within the pharmaceutical sector, Haier Biomedical is integral to the supply chains of leading pharmaceutical companies in key countries, including Switzerland, Germany, Denmark, Italy, Singapore, the USA, Israel, and India. Its Ultra Energy series holds all eight top positions in the US Energy Star rankings within its category, solidifying its status as the best-selling product line in this segment.
Looking to the future, Haier Biomedical plans to deepen its investment in localization and expand its product offerings to assist global biopharmaceutical and biological laboratories in enhancing their efficiency and sustainability. This initiative aligns with the company's vision to become the world's leading provider of integrated tools for life sciences and intelligent productivity platforms. For more information about Haier Biomedical and its groundbreaking services, visit https://www.haiermedical.com/.
Euromonitor International stands as one of the leading independent market research firms worldwide. Its rankings serve as essential benchmarks in global procurement and industry analysis, confirming Haier Biomedical's competitive stance against other major players in the market. The dual acknowledgment is particularly significant for international partners, as it reinforces a sense of trust and credibility essential for procurement decisions in an industry where equipment reliability, regulatory compliance, and long-term service support are critical.
Haier Biomedical's international growth trajectory began with targeted initiatives and direct collaborations with organizations like UNICEF and WHO, addressing unmet needs and securing a leading position in solar-powered vaccine storage solutions. From this foundation, the company has expanded its distribution network to 160 countries through over 800 active sales partnerships. The current phase of the company's strategy focuses on implementing comprehensive operational capabilities across key regions, including local storage, sales, marketing, product planning, and R&D.
The company presently operates R&D centers in the UK, Italy, and Japan. Each center is dedicated to specific product lines, such as centrifuges, cold chain solutions, automated storage systems, incubators, and biological safety cabinets. In the UK and continental Europe, automation specialists and centrifuge technology experts provide localized support, ensuring compliance with Good Manufacturing Practices (GMP), air safety protocols, and sample processing cleanliness.
Haier Biomedical continues to enhance its service standards, developed initially in the USA and UK, replicating best practices across the EU, Southeast Asia, and South Asia. Notably, in the first quarter of 2026, revenue growth surged more than 50% in Germany, Australia, and Canada, while Eastern Europe, South Asia, and Brazil reported over a 100% year-over-year growth. Notably, sales of centrifuges and incubators doubled during this period, underscoring the company's rapid market penetration.
Within the pharmaceutical sector, Haier Biomedical is integral to the supply chains of leading pharmaceutical companies in key countries, including Switzerland, Germany, Denmark, Italy, Singapore, the USA, Israel, and India. Its Ultra Energy series holds all eight top positions in the US Energy Star rankings within its category, solidifying its status as the best-selling product line in this segment.
Looking to the future, Haier Biomedical plans to deepen its investment in localization and expand its product offerings to assist global biopharmaceutical and biological laboratories in enhancing their efficiency and sustainability. This initiative aligns with the company's vision to become the world's leading provider of integrated tools for life sciences and intelligent productivity platforms. For more information about Haier Biomedical and its groundbreaking services, visit https://www.haiermedical.com/.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.